Age-Related B Cell Dysfunction At The Aging-Cancer Nexus: From Shared Manifestations To Therapeutic Potential
As we age, our bodies undergo many changes, and our immune system is no exception. While much attention has been paid to how T cells, a type of immune cell, change with age, it’s becoming increasingly clear that B cells, another crucial type of immune cell responsible for producing antibodies, also experience significant alterations. These changes in B cells are not just a consequence of getting older; they are also deeply intertwined with the development and progression of cancer.
Researchers are now understanding that age-related B cell dysfunction involves several key issues. For instance, the ability of B cells to mount effective immune responses, like those needed to fight off infections or target cancer cells, becomes impaired. There’s also a decline in the diversity of B cells, meaning our immune system has fewer tools to recognize and combat a wide range of threats. Furthermore, B cells can become more prone to promoting inflammation and even attacking our own healthy tissues, a process known as autoreactivity.
These age-related shifts in B cell function are linked to fundamental biological hallmarks shared by both aging and cancer. These include damage to our genetic material (genomic instability), changes in how our genes are expressed (epigenetic reprogramming), persistent low-grade inflammation, and imbalances in our body’s microbial communities (dysbiosis). All these factors profoundly reshape how our immune cells behave.
Understanding these maladaptive B cell programs across different tissues and in the context of tumors is crucial. These alterations can influence how tumors grow, how they respond to various therapies, and even contribute to treatment-related side effects. The good news is that by gaining insights into these age-related B cell dysfunctions, scientists are identifying new strategies to target these problematic B cells in cancer, paving the way for innovative therapeutic approaches that leverage our knowledge of both aging biology and tumor immunology.
Source: link to paper